Our Take
Whoop capitulated on clinical claims rather than fighting the FDA's device classification—a pragmatic choice that keeps the product shipping but narrows what the company can legally claim it does.
Why it matters
Consumer wearables operate in a gray zone between wellness tracking and medical device regulation. How Whoop resolves this sets precedent for other fitness trackers adding health metrics.
Do this week
Product teams: audit any health-related claims in your wearable or app against FDA guidance on clinical vs. wellness positioning before you ship, or you'll face the same remediation cycle Whoop just completed.
Whoop resolved FDA enforcement action by reframing blood pressure
The FDA dropped its warning letter to Whoop after the wearable maker modified its blood pressure insights feature to comply with regulatory requirements for wellness devices. Whoop changed how the feature operates and is positioned to users, shifting the classification away from a medical claim.
The letter, originally issued because the FDA considered Whoop's blood pressure feature a medical device requiring premarket review, has now been withdrawn. Whoop's modifications satisfied the agency's requirements without requiring the company to abandon the feature entirely.
The gray line between wellness and diagnosis keeps moving
Wearables occupy contested regulatory territory. A feature that tracks heart rate may be wellness; a feature that detects atrial fibrillation is a medical device. The FDA has been inconsistent about where to draw that line, and enforcement actions like Whoop's are how the agency signals its current interpretation.
Whoop's retreat from clinical positioning does not mean blood pressure tracking is illegal. It means Whoop cannot claim its feature diagnoses, treats, or predicts hypertension. The company can still measure and report the data—but in language that keeps the FDA out of its product roadmap.
Other wearable makers watching this will now know the cost of claiming too much. Apple Watch got away with ECG and AFib detection partly because it fought and negotiated with the FDA early. Whoop chose speed and retreat instead.
Classify claims before you ship
If your product measures a health signal, decide now whether you are claiming to diagnose, treat, or predict disease. If yes, budget 12-24 months and $1M+ for FDA review. If no, audit every word in your UI, marketing, and support docs to ensure you are not creeping into clinical language. The FDA reads app store descriptions and user-facing copy. One stray claim about "detecting" or "preventing" a condition can trigger a warning letter. Whoop's fix required redesign and repositioning. Yours does not have to.